On Friday, Shares of Bank of America Corporation (NYSE:BAC), gained 2.44% to $17.19, as financial stocks ended higher with the NYSE Financial Sector Index climbing just 0.1% while the S&P Financial 100 Index was posting a 0.6% gain.
119,088,858 shares traded on Friday as compared to its average volume of 75,550,900 shares. The company has the market capitalization of 180.53B.
Bank of America Corporation, through its auxiliaries, provides banking and financial products and services for individual consumers, small and middle market businesses, institutional investors, large corporations, and governments worldwide.
Shares of Nokia Corporation (NYSE:NOK), declined -3% to $7.12, during its last trading session, as technology stocks were falling Friday with shares of technology companies in the S&P 500 dropping about 0.3%.
The company exchanged hands with 11,274,330 shares as compared to its average daily volume of 29,773,800 shares. The company holds the market capitalization of 25.80B.
Nokia Corporation, together with its auxiliaries, provides network infrastructure and related services in Finland, the United States, Japan, China, India, the Russian Federation, Germany, Taiwan, Indonesia, Italy, and internationally. The company operates through four segments: Mobile Broadband, Global Services, HERE, and Nokia Technologies.
At the end of Friday’s trade, Shares of Oasis Petroleum Inc. (NYSE:OAS), gained 2.02% to $16.66, after some energy and related stocks rally together with the price of oil.
Oil prices rose Friday on a drop in U.S. drilling, but posted a decline for the week as a stronger dollar and continued oversupply of crude oil weighed on the market.
Light, sweet crude for July delivery settled up $1.13, or 1.9%, at $59.13 a barrel on the New York Mercantile Exchange. Prices fell 1.9% this week.
Brent, the global benchmark, rose $1.28, or 2.1%, to $63.31 a barrel on ICE Futures Europe, posting a 3.4% weekly loss.
Oasis Petroleum Inc., an independent exploration and production company, focuses on the acquisition and development of unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin.
Finally, Neurocrine Biosciences Inc. (NASDAQ:NBIX), ended its last trade with 4.84% surge, and closed at $43.51.
Neurocrine Biosciences, declared that Eric Benevich has joined the company as Chief Commercial Officer.
Mr. Benevich was most recently at Avanir Pharmaceuticals as Vice President of Marketing where he was responsible for NUEDEXTA® and commercialization of their CNS pipeline. He has over twenty years of previous experience in the pharmaceutical industry with Peninsula Pharmaceuticals, Amgen and AstraZeneca in the sales and marketing of drugs such as Enbrel®, Epogen® and Prilosec®. Eric has a BBA in international business from Washington State University.
Neurocrine also declared the grant of an inducement award to Mr. Benevich following Rule 5635(c)(4) of the NASDAQ Listing Rules. In connection with his employment with Neurocrine, Mr. Benevich was granted an inducement award compriseing of a stock option to purchase 60,000 shares of Neurocrine common stock. The stock option will vest over a period of four years, with 25% vesting on the first anniversary of the grant date and the balance vesting each month over the remaining three years. Mr. Benevich also received 25,000 restricted stock units which vest in full after three years of continuous service. These awards are subject to the terms and conditions of Neurocrine’s Inducement Plan. These awards were effective on June 1, 2015, the first business day of the first calendar month following the commencement of his employment with Neurocrine, and the stock option has an exercise price of $41.78 per share, which was the closing price of Neurocrine’s common stock on the NASDAQ Global Select Market on that date. The award was granted as an inducement material to Mr. Benevich’s employment following Rule 5635(c)(4) of the NASDAQ Listing Rules.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage comprise elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
